Kolexia
Kaczmarek Emilie Gynécologie
Kaczmarek Emilie
Gynécologie
Centre Oscar-Lambret
Lille, France
51 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Carcinome épithélial de l'ovaire Tumeurs de l'ovaire COVID-19 Carcinomes Ascites Fièvre Infertilité Tumeurs de la trompe de Fallope

Collaborateurs

Voir plus
Kokorian Romain
Kokorian Romain
Cabinet libéral, Rouen, France
Zouhry Yacine
Zouhry Yacine
Cabinet libéral, Angoulême, France
Benziane Ouaritini Nicolas
Benziane Ouaritini Nicolas
Institut Bergonié, Bordeaux, France
Rotarski Maciej
Rotarski Maciej
Centre D'oncologie Et De Radiotherapie, Bayonne, France

Industries

Voir plus
B3TSI
235 collaboration(s)
Dernière en 2023
A+A
8 collaboration(s)
Dernière en 2023
EXAFIELD
6 collaboration(s)
Dernière en 2023
Pfizer
6 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Essai Clinique (Seagen)   15 mars 2024
TILsOV-1805: Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Advanced High-grade Serous Ovarian Cancer in Blood, Ascites, Peritoneal Biopsy
Essai Clinique (Centre Oscar-Lambret)   08 février 2024
TEDOVA: Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy
Essai Clinique (Merck & Co.)   04 décembre 2023
386MO Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
CHACRY-1501: Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation (CHACRY-1501)
Essai Clinique (Centre Oscar-Lambret)   13 février 2023
CHIPPI: Phase III Randomized Clinical Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer Considering Two Different Settings: Primary Debulking Surgery (PDS) and Interval Debulking Surgery (IDS)
Essai Clinique (Centre Oscar-Lambret)   06 décembre 2022
16 Months Follow Up of Patients' Behavior and Mild COVID-19 Patterns in a Large Cohort of Cancer Patients During the Pandemic.
Frontiers in oncology   07 juin 2022
CTC-SMMiL-E: Feasibility of a New Technology for Isolating Circulating Tumour Cells in Selected Cancer Patients and Healthy Volunteers
Essai Clinique (Centre Oscar-Lambret)   05 octobre 2021
Abstract PS1-58: The role of resection of the primary tumour in patients with de novo oligometastatic breast cancer (OMBC)
Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium   15 février 2021
OMERIC: Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer (OMERIC): A Cohort Study
Essai Clinique (Centre Oscar-Lambret)   27 novembre 2020